Clinical study on effect of tongluo capsule in treating diabetic nephropathy caused chronic renal failure.
- Author:
	        		
		        		
		        		
			        		Wan-sen SUN
			        		
			        		
			        		
			        			1
			        			
			        		
			        		
			        		
			        		
			        		;
		        		
		        		
		        		
			        		Xi-li WU
			        		
			        		;
		        		
		        		
		        		
			        		Cheng-lin QIAO
			        		
			        		
		        		
		        		
		        		
			        		
			        		Author Information
			        		
 - Publication Type:Clinical Trial
 - MeSH: Adult; Albuminuria; drug therapy; Blood Urea Nitrogen; Capsules; Creatinine; blood; Diabetic Nephropathies; complications; drug therapy; Drugs, Chinese Herbal; therapeutic use; Female; Humans; Kidney Failure, Chronic; drug therapy; etiology; Lipids; blood; Male; Middle Aged; Phytotherapy; Tongue; Transforming Growth Factor beta; blood; Transforming Growth Factor beta1
 - From: Chinese Journal of Integrated Traditional and Western Medicine 2004;24(8):704-706
 - CountryChina
 - Language:Chinese
 - 
		        	Abstract:
			       	
			       		
				        
				        	
OBJECTIVETo observe the therapeutic effect of Tongluo capsule (TLC) in treating diabetic nephropathy (DN) complicated chronic renal failure (CRF), and to explore its mechanism preliminarily.
METHODSNinety-seven patients with DN-CRF were randomly divided into the TCM group (n = 50) and the WM group (n = 47) to observe the changes of urinary protein per 24 hrs (UP/24h), renal function, creatinine (Cr), blood urea nitrogen (BUN), blood lipids (TG, TC, HDL-C, LDL-C) and serum transforming growth factor-beta1 (TGF-beta1) before and after treatment.
RESULTSAfter 6 months of treatment, levels of UP/24h, Cr, BUN and TGF-beta1 significantly lowered in both groups (P<0.01), and a better effect was showed in the TCM group in aspects of lowering Cr, BUN and TGF-beta1 (P<0.01). Besides, TLC also showed effect in lowering the serum lipid parameters (P<0.05 or P<0.01).
CONCLUSIONEffect of TLC in treating DN-CRF might be through lowering the levels of blood lipids and serum TGF-beta1.
 
            